Immunovant CEO Eric Venker disposes of common shares worth $2.93 million
IMVT•Immunovant CEO and director Eric Venker disposed of shares worth $2.93 million, while his direct stake rose to 257,075 shares following a CVAR settlement.
1. Share transactions
Venker acquired 92,187 shares on Oct. 1, 2026, at $14.46 per share through an exercise transaction. He disposed of 85,886 shares that day at $33.65 per share and sold another 3,506 shares on Oct. 2 at $34.11 per share to cover tax withholding.
